Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
12
Industry P/E
--
Debt to Equity
--
ROE
-1.49 %
ROCE
-148.73 %
Div. Yield
0 %
Book Value
0.37
EPS
-1.59
CFO
$-25.27 Mln
EBITDA
$-34.42 Mln
Net Profit
$-35.48 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lixte Biotechnology Holdings (LIXT)
| -36.94 | -4.48 | -46.76 | -60.98 | -52.57 | -52.69 | -20.05 |
|
BSE Sensex*
| 2.60 | 3.45 | 6.52 | 8.88 | 12.21 | 20.39 | 11.44 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lixte Biotechnology Holdings (LIXT)
| -13.53 | -53.83 | -57.14 | -62.46 | -22.19 | -27.03 | 456.04 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b... clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Read more
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
Headquarters
Pasadena, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lixte Biotechnology Holdings Inc (LIXT) stood at $ 1 Mln as on 31-Dec-24
The share price of Lixte Biotechnology Holdings Inc (LIXT) is $1.28 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Lixte Biotechnology Holdings Inc (LIXT) has given a return of -52.57% in the last 3 years.
Lixte Biotechnology Holdings Inc (LIXT) has a market capitalisation of $ 3 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lixte Biotechnology Holdings Inc (LIXT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lixte Biotechnology Holdings Inc (LIXT) and enter the required number of quantities and click on buy to purchase the shares of Lixte Biotechnology Holdings Inc (LIXT).
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
The CEO & director of Mr. Bastiaan van der Baan M.Sc.. is Lixte Biotechnology Holdings Inc (LIXT), and CFO & Sr. VP is Mr. Bastiaan van der Baan M.Sc..
There is no promoter pledging in Lixte Biotechnology Holdings Inc (LIXT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Lixte Biotechnology Holdings Inc. (LIXT) | Ratios |
|---|---|
|
Return on equity(%)
|
-148.73
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lixte Biotechnology Holdings Inc (LIXT) was $0 Mln.
$0.02
(
